Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
BACKGROUND
A promising treatment approach for patients with malignant disease that recently has found its way into clinical trials is based on vaccination with autologous dendritic cells loaded with tumor antigens. However, adequate assays for monitoring clinical and immunologic responses still are under debate. In recent years, the determination of angiogenic markers has shown considerable potential in the diagnosis and prognosis of patients with malignant disease, because tumor growth and spread are promoted by angiogenesis, the formation of new blood vessels.


METHODS
The authors established a method for measuring the plasma levels of three modulators of angiogenesis: vascular endothelial growth factor, platelet-derived endothelial cell growth factor, and thrombospondin-1. The angiogenic blood profile of a healthy control group was characterized and compared with a group of patients with malignant disease. Ultimately, levels of circulating angiogenic factors were monitored in the course of dendritic cell-based cancer immunotherapy.


RESULTS
Baseline levels of angiogenic mediators varied substantially among healthy individuals but showed consistent values for each individual. Blood levels of circulating angiogenic factors were elevated significantly in patients with advanced disease and were highly sensitive to dendritic cell-based immunotherapy.


CONCLUSIONS
To our knowledge, the current report was the first to analyze circulating levels of angiogenic factors during dendritic cell-based immunotherapy. The authors observed a noteworthy change in the angiogenic blood profile with treatment, and this change was correlated with the induction of an immunologic response.
Department of General Surgery, General Hospital, University of Vienna, Vienna, Austria. christine.brostjan@univie.ac.at
Christine
C
Brostjan
Anita
A
Bayer
Anna
A
Zommer
Alexander
A
Gornikiewicz
Sebastian
S
Roka
Thomas
T
Benkö
Rubina
R
Yaghubian
Raimund
R
Jakesz
Günther
G
Steger
Michael
M
Gnant
Josef
J
Friedl
Anton
A
Stift
D000328:Adult; D015415:Biomarkers / Q000097:blood*; D019496:Cancer Vaccines / Q000276:immunology / Q000494:pharmacology*; D003713:Dendritic Cells; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D009389:Neovascularization, Pathologic; D019700:Thrombospondin 1 / Q000097:blood*; D013939:Thymidine Phosphorylase / Q000097:blood*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D015415:Biomarkers; D019496:Cancer Vaccines; D019700:Thrombospondin 1; D042461:Vascular Endothelial Growth Factor A; D013939:Thymidine Phosphorylase